https://www.selleckchem.com/products/art0380.html
Dalcinonacog alfa (DalcA), a next-generation, recombinant human factor IX (FIX) variant, was developed using a rational design approach for increased procoagulant activity and longer duration of action to be administered subcutaneously (SC) for prophylaxis of hemophilia B bleeding episodes. To investigate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of DalcA. This multicenter, phase 1/2a study (NCT03186677) was conducted in 11 males aged 12 to 65years with severe hemophilia B. In cohort 1, subjects received intravenous (
Like
Comment
Share
